Why Your Antidepressant Stopped Working After a Few Months

Antidepressant tachyphylaxis, sometimes called "poop-out," is when an SSRI that worked for months stops holding your mood steady even though you never missed a dose. It is not relapse and not tolerance. A prescriber should first confirm adherence, screen for drug interactions and thyroid problems, then raise the dose, switch drugs, or add an augmenting agent such as bupropion.

The pattern is specific. You felt better for three, six, nine months on 20 mg of escitalopram, and then the floor gave way again while the pill bottle stayed the same. Estimates put tachyphylaxis at 9-33% of long-term antidepressant users, a range that wide because studies disagree on whether "loss of response" means a full return of symptoms or a partial one. Either way, the number is large enough that most prescribers have seen it repeatedly.

Patients often assume the drug has stopped working because their body "got used to it." That framing pushes toward a higher dose, which is sometimes right and sometimes exactly wrong. Tolerance means you need more drug for the same effect; tachyphylaxis is loss of effect at a stable dose; relapse means symptoms returned after you stopped. The distinction changes what gets prescribed next.

One thing that reliably goes wrong is abrupt discontinuation. Roughly 20% of people who stop an SSRI suddenly get discontinuation syndrome, which can look like worsening depression and lead everyone, patient and clinician, to chase the wrong problem.

• Not a relapse: Relapse means symptoms returned after you stopped the drug; tachyphylaxis means the drug is still in your system and no longer working.
• Switch rates: A 2019 systematic review in Psychotherapy and Psychosomatics found that switching to a different antidepressant resolved poop-out in roughly 50-60% of cases.
• Augmentation options: Adding bupropion or aripiprazole, supported by the STAR*D trial, produces response in about 30-50% of patients within 6-8 weeks.
• Rule out mimics: Before any change, prescribers should check TSH for hypothyroidism, vitamin B12 levels, and interactions with drugs like omeprazole or rifampin.
• Do not stop cold: Discontinuation syndrome occurs in about 20% of people who quit an SSRI suddenly and can be mistaken for a worsening depressive episode.

What is antidepressant tachyphylaxis (poop-out)?

Tachyphylaxis is the loss of a drug's therapeutic effect after a period of genuine response, at a stable dose, with no new life stressor and no missed doses to explain it. In the antidepressant literature this is often called "poop-out," and it usually shows up between three and twelve months after someone has stabilised. The defining feature is the sequence: you responded, you stayed on the same milligram count, nothing external changed, and the drug quietly stopped doing what it was doing. A 2019 review in Psychotherapy and Psychosomatics estimated that somewhere between 9% and 33% of long-term antidepressant users experience this, which is a wide range because studies define and measure it differently, but it is not a rare event.

Tachyphylaxis is not the same as tolerance, and the difference matters for what your prescriber does next. Tolerance means the same dose produces a smaller effect, so you need more drug to get back to where you were. Tachyphylaxis means the effect fades at a dose that used to work, and simply raising the dose often fails to restore it. That is the trap a lot of people fall into: the dose goes up, they feel marginally better for a few weeks, then slide again. Tachyphylaxis is also not withdrawal. Discontinuation syndrome happens when you stop an SSRI abruptly and occurs in roughly 20% of patients who do so, producing flu-like symptoms, dizziness and "brain zaps" that resolve once the drug is back in your system. Nor is it a relapse. A relapse is the underlying illness returning; tachyphylaxis is the drug losing its grip while the illness itself has not necessarily changed.

None of this is a reason to stop taking your medication on your own, and it is worth being explicit about why. Abrupt withdrawal from a short-half-life SSRI like paroxetine, which clears in about 21 hours, can be considerably rougher than stopping fluoxetine, which lingers for 4 to 6 days. The clinical response to confirmed tachyphylaxis is a structured reassessment, not a reflex dose increase, and the two main paths are switching to a different antidepressant or augmenting the current one. STAR*D, the large US trial published in 2006, found that patients who switched after a first antidepressant failure reached remission 21% to 30% of the time within 14 weeks, and augmentation with bupropion produced a 30% remission rate over the same window. A 2018 study in the Journal of Affective Disorders found that 50% to 60% of poop-out patients responded to a switch within 8 weeks, which is a reasonable argument for changing drugs rather than pushing the same one harder.

How can I tell if it's poop-out, a relapse, or just a bad week?

The timeline does most of the work. Tachyphylaxis, or poop-out, is defined by a stretch of genuine stability followed by decline: at least 2–3 months of feeling like yourself on a steady dose, then a slow slide. If you stopped your sertraline or escitalopram, or missed four or five doses in the past fortnight, that is far more likely to be discontinuation syndrome or a straight relapse than poop-out. Roughly 20% of people who stop SSRIs abruptly get withdrawal symptoms, per a 2020 review, and they can mimic depression closely: low mood, crying spells, irritability, disturbed sleep.

Symptom pattern is the second filter. Poop-out usually creeps in over weeks without a clear trigger and feels like walking backwards to where you started. Relapse tends to follow a stressor you can name—a bereavement, a job loss, a bad winter—or a dose change. Seasonal patterns matter too: if this happens every October and lifts by April, you are describing seasonality, not tachyphylaxis.

If your answers sit mostly in column two and you have been stable for three months or more at an unchanged dose, treat it as tachyphylaxis and book an appointment rather than waiting it out. The evidence here is stronger than most people are told: a 2018 study in the Journal of Affective Disorders found that 50–60% of poop-out patients responded to a switch within 8 weeks, and STAR*D (2006) showed switching to a new antidepressant produced remission in 21–30% of patients by 14 weeks, with bupropion augmentation hitting 30%. Dose escalation, by contrast, tends to buy only a few months before the same flattening returns. The flip case is anyone who missed doses or stopped in the last month: do not switch drugs yet. Restart the original medication at the original dose, hold for 4–6 weeks, and reassess. Chasing a switch when the real problem was three missed paroxetine tablets—half-life around 21 hours, versus 4–6 days for fluoxetine—wastes months and costs you a working drug.

Why does this happen? The leading theories

The honest answer is that nobody has a settled mechanism. What exists is a set of competing explanations, each with some supporting evidence and none with enough to close the case. A 2019 review in Psychotherapy and Psychosomatics estimated that somewhere between 9% and 33% of long-term antidepressant users lose response this way, a range wide enough to tell you how imprecise the measurement still is.

The most-cited hypothesis is receptor desensitization. SSRIs raise synaptic serotonin within hours, but clinical improvement takes two to six weeks because the brain adapts: 5-HT1A autoreceptors on the raphe nuclei gradually downregulate, which lets serotonin signalling increase. The theory behind poop-out is that some of this adaptation overshoots or reverses, leaving the 5-HT1A system less responsive than it was at month three. It fits the timeline. It has never been confirmed in living patients, because you cannot measure autoreceptor density in someone's brain without a PET scanner and a research budget.

Pharmacokinetic explanations get less attention than they deserve. Several antidepressants are metabolized through CYP2D6 and CYP3A4, and those enzymes can be induced over months by other drugs — carbamazepine, rifampin, even St John's wort — which lowers plasma levels of the antidepressant without any change in dose. Smoking does something similar. If someone started an additional medication in month four and felt worse in month six, that is a drug interaction, not tachyphylaxis, and the fix is a dose adjustment or a switch rather than a new diagnosis. This is checkable. A plasma level or a careful medication review can rule it in or out, which is more than can be said for the receptor theory.

Progression versus adaptation

Then there is the uncomfortable possibility that the underlying illness has simply moved. Depression is often recurrent and progressive; each episode tends to be longer and harder to treat than the last, and a drug that worked on episode two may not hold episode four. Neuroplasticity research — BDNF signalling, hippocampal volume changes — suggests the brain's response to chronic stress can outrun what a single reuptake inhibitor can compensate for. Under this model, the medication did not stop working. The target moved.

These three explanations are not mutually exclusive, and in practice a prescriber often cannot tell which is operating. That matters for what happens next. If the cause is a CYP interaction, the answer is a dose correction. If it is receptor adaptation or illness progression, a switch or an augmentation has better odds — switching after a first failure produced remission in 21–30% of STAR*D participants at 14 weeks, and bupropion augmentation reached roughly 30%. Before any of that, though, standard practice is to check thyroid-stimulating hormone (TSH) and vitamin B12, because hypothyroidism and B12 deficiency both mimic depression relapse and both are cheap to rule out.

What should your prescriber check first?

Before anyone touches the dose, your prescriber should be able to write down a reason for what changed. Tachyphylaxis is a diagnosis of exclusion — it looks identical to a relapse, a new stressor, an untreated thyroid problem, or a drug interaction that crept in six weeks ago. Roughly 9–33% of long-term antidepressant users experience it, which is a wide enough range to tell you the label gets applied loosely. The workup below is the standard order most psychiatrists follow; expect it to take one or two appointments, not one ten-minute phone call.

• Confirm adherence and timing, with specifics. Ask how many doses were missed in the last 30 days, not "are you taking it." Sertraline and escitalopram are usually taken in the morning; fluoxetine is often moved to the morning because it is activating. Paroxetine has a half-life of about 21 hours, so a missed dose there produces withdrawal symptoms within a day and gets misread as a mood crash. If you take it with food, say so — nausea-driven skipping is common and rarely volunteered.
• Order a thyroid panel. Thyroid-stimulating hormone (TSH) is the single highest-yield lab here. Subclinical hypothyroidism affects roughly 4–10% of adults and presents as low mood, fatigue and poor concentration, which is indistinguishable from poop-out. A TSH above about 4.5 mIU/L in a symptomatic person usually justifies a free T4 and a conversation about treatment.
• Check vitamin B12, vitamin D, and a complete blood count. B12 deficiency below roughly 200 pg/mL causes depression and cognitive fog, and it is far more common in people over 60, vegans, and anyone on long-term metformin or a proton-pump inhibitor. Ferritin matters too; iron deficiency with a normal haemoglobin still produces fatigue and low mood, and it is routinely missed.
• Review every other medication and supplement. This is where the drug interaction lives. Omeprazole and other proton-pump inhibitors can raise or lower plasma levels of some SSRIs depending on which enzyme handles them. Rifampin is a potent CYP inducer and will drop escitalopram and citalopram levels hard. St. John's wort induces CYP3A4 and can both reduce your antidepressant's effect and, if combined carelessly, push you toward serotonin syndrome.
• Ask specifically about alcohol, cannabis and sleep. Two drinks most nights is enough to blunt SSRI response in some people, and daily cannabis use is associated with poorer antidepressant outcomes in cohort data. Neither shows up on a lab slip, so it only surfaces if the prescriber asks directly and without a lecture.
• Screen for bipolar spectrum illness. If there was ever a period of several days with unusually high energy, reduced sleep need, or uncharacteristic spending, an SSRI alone may be the wrong drug entirely. Antidepressant monotherapy in bipolar II can produce rapid cycling that reads as treatment failure. Tools like the MDQ take about five minutes.
• Quantify the change with a scale, not a feeling. A PHQ-9 at the last stable visit and one today gives you a number. A rise from 6 to 11 is different from a rise from 6 to 19, and it changes whether the answer is watchful waiting, a switch, or augmentation.

The step people skip is the interaction review, because it feels like it was already done at the first prescription. It was — but that was months ago, and the omeprazole, the antibiotic course, the new supplement for sleep, or the St. John's wort a friend recommended all arrived since. That single oversight accounts for a meaningful share of what gets labelled tachyphylaxis, and it is the cheapest thing on the list to rule out.

What are the typical next steps?

Once your prescriber has ruled out the obvious confounders—an untreated thyroid problem, a B12 deficiency, a new medication interacting through CYP2D6—the conversation usually narrows to three moves: push the dose, switch the drug, or add a second agent. Dose increase is the first thing most people try, partly because it is easy and partly because it sometimes works. A bump from 50 mg to 100 mg of sertraline buys real improvement in a minority of cases. The problem is durability. Response to a raise in a true tachyphylaxis picture tends to fade within weeks to a few months, and you pay for it in side effects that scale with dose: sexual dysfunction, sweating, emotional flattening, and sleep disruption. A raise is a reasonable short trial, not a long-term plan.

Switching has the better evidence base. The STAR*D trial, published in 2006, found that patients who had failed a first antidepressant and moved to a different one reached remission at rates of 21–30% by 14 weeks. A 2018 study in the Journal of Affective Disorders looked specifically at poop-out patients and found 50–60% responded to a switch within 8 weeks. You can switch within the same class—sertraline to escitalopram, for instance—or cross over to a different mechanism such as venlafaxine. Within-class switches are gentler on the body and easier to tolerate; out-of-class switches may capture people whose original response was partial to begin with. Either way, the taper matters. Half-lives differ enormously: fluoxetine runs 4–6 days, paroxetine about 21 hours. That gap determines whether you need a washout to avoid serotonin syndrome or whether you can move directly. Roughly 20% of people who stop SSRIs abruptly get discontinuation syndrome, so a planned cross-taper with your prescriber is not optional.

When switching isn't enough: augmentation

Augmentation means keeping the current antidepressant and adding a second drug with a different action. In STAR*D, adding bupropion produced a 30% remission rate at 14 weeks, and it has the advantage of offsetting SSRI-related sexual side effects and fatigue. Aripiprazole, an atypical antipsychotic, has stronger numbers in some analyses—a 2016 meta-analysis put its number needed to treat at 7 for response—but it brings weight gain, akathisia, and metabolic monitoring. Liothyronine, a synthetic thyroid hormone, is the quieter option and is named in NICE guidelines as a reasonable adjunct; it works for a subset of people who never fully remitted on an SSRI alone.

Which path is right depends on how you responded the first time. If you had a clean, full remission for months and then lost it, switching is usually the better bet—your brain has already told you it can respond to this class of drug, and the evidence for a cross-taper is stronger than for stacking. If you never quite got all the way well, augmentation makes more sense, because you are treating an incomplete response rather than a lost one. Whichever you and your prescriber choose, give it 6–8 weeks at a therapeutic dose before judging it, and keep psychotherapy in the picture; the combination outperforms medication alone in most of the trials that compare them.

Switching antidepressants: what to expect

This applies when you and your prescriber have already ruled out thyroid problems, B12 deficiency and a plain relapse, and have decided the current drug has genuinely stopped pulling its weight. A switch needs one thing before anything else: a current medication list, including anything you buy over the counter. Cold and flu remedies and migraine tablets contain serotonergic drugs more often than people realise.

1. Do not stop the old antidepressant on your own. Abrupt cessation of an SSRI causes discontinuation syndrome in roughly 20% of patients, according to a 2020 review — dizziness, electric-shock sensations, nausea, irritability — typically within one to three days and lasting one to two weeks. That feels like relapse and gets misread as one. If you want out, say so and get a plan.
2. Your prescriber picks the switching method, and it depends mostly on half-life. Fluoxetine sits at 4–6 days, paroxetine at roughly 21 hours. A long half-life drug is largely self-tapering, so a direct switch is often workable. Short half-life drugs such as paroxetine and venlafaxine usually need a cross-taper, where the dose of the old drug comes down while the new one comes up.
3. A cross-taper is typically run over one to four weeks, adjusted to how you tolerate it. Sertraline to escitalopram at equivalent doses moves faster than anything involving fluoxetine, which lingers and can interact with the incoming drug for days after you stop taking it.
4. A washout — a drug-free gap of several days to a couple of weeks — is now uncommon in outpatient care. It is mainly used when moving between drugs with a real risk of interaction, such as an MAOI. If you are prescribed one, the gap is not optional.
5. Watch for serotonin syndrome whenever two serotonergic drugs overlap. This is the step people botch, because overlap is the point of a cross-taper and the early symptoms look like ordinary anxiety or flu. Agitation, sweating, shivering, muscle twitching, fast heart rate and dilated pupils appearing within hours to a day of a dose change need urgent contact with a clinician, not a wait-and-see. Severe cases involve fever above 38.5°C, rigidity and confusion, and are a 999 or 911 call.
6. Expect side effects first. Two to four weeks covers most of the nausea, headache, sleep disruption and jitteriness that come with starting a new drug, and they usually fade. Full antidepressant effect takes six to eight weeks, sometimes longer at a sub-therapeutic starting dose.
7. Ask about CYP2D6 before assuming a drug "just doesn't work for you". This liver enzyme handles paroxetine, fluoxetine and venlafaxine, and poor metabolisers can build up levels that produce side effects at standard doses. A test costs roughly £150–£300 privately in the UK and is not routine on the NHS.

On the odds: the STAR*D trial, published in 2006, found that switching to a new antidepressant after a first failure produced remission in 21–30% of patients by 14 weeks. A 2018 study in the Journal of Affective Disorders put response among poop-out patients after a switch at 50–60% within 8 weeks. Those numbers are not identical and the reason is partly how "response" and "remission" were defined, partly the different populations. Both are better than staying on a drug that has stopped working.

The failure mode is deciding the switch failed on day 12. Side effects at that point mean little about whether the drug will work, and stopping early lands you back at zero with a discontinuation syndrome on top. The other failure is the opposite: eight weeks go by, you feel no better, and nobody revisits the plan. Set a review date at the start. If 6–8 weeks at an adequate dose brings nothing, that is information, not a reason to keep waiting. Augmentation is the usual alternative — bupropion added to an SSRI gave a 30% remission rate at 14 weeks in STAR*D, and aripiprazole augmentation has a number needed to treat of 7 for response, per a 2016 meta-analysis — but that is a different conversation, and the NICE guidelines sequence it after an adequate switch trial.

Can you prevent poop-out?

No one has shown that any drug strategy prevents tachyphylaxis. That is the blunt version, and it is worth saying because the internet is full of supplements, "SSRI tolerance" protocols and dose-scheduling tricks that have never been tested against a placebo. What the evidence does support is a smaller set of behaviours: taking the drug as prescribed, keeping an accurate symptom record, and staying in contact with a prescriber rather than drifting away once you feel well. The 9–33% figure from a 2019 review is an estimate of how often this happens across long-term users, not a risk score you can move with a lifestyle change.

The strongest secondary evidence points at psychotherapy. Long-term follow-up from the STAR*D cohort (2006) and a body of work published in journals such as Psychotherapy and Psychosomatics suggests that people who combine medication with structured therapy hold their response longer than those on medication alone, though the trials were not designed to measure tachyphylaxis specifically. Exercise has similar, softer support: a 2023 meta-analysis of aerobic exercise in major depression found moderate effect sizes on symptom scores, and several smaller studies report that 150 minutes a week of moderate activity is associated with sustained improvement. Neither is a guarantee. Both are cheap, low-risk, and reasonable to start while you wait for an appointment.

The things that actually go wrong

Self-adjusting the dose is the most common mistake, and it cuts both ways. Skipping doses or halving sertraline or escitalopram to "reset" can trigger discontinuation syndrome, which a 2020 review puts at roughly 20% of people who stop SSRIs abruptly; short half-life drugs such as paroxetine, at about 21 hours, hit hardest, while fluoxetine at 4–6 days usually fades more gently. Going the other direction without supervision does not fix anything either. Doubling your dose for a few weeks is not a recognised treatment for tachyphylaxis, it exposes you to side effects on a timeline you cannot assess, and if your prescriber later wants to switch, dose history matters for the washout calculation.

Adherence is more interesting than it sounds. Most people who report poop-out are, on testing, taking the medication correctly. But a subset of apparent tachyphylaxis turns out to be inconsistent timing, missed doses around holidays, or a new generic manufacturer with different excipients. If you are going to do anything before your next appointment, keep a dated log of symptoms, sleep hours, alcohol intake, and dosage times for two weeks. That single sheet of paper is what makes a prescriber-guided reassessment possible rather than guesswork.

When to call your doctor immediately

Tachyphylaxis is not an emergency. It is a slow fade over weeks, and it can usually wait for a scheduled appointment. The symptoms below are different. They signal that something is happening faster than a receptor downregulation curve, and they need a same-day phone call or an emergency department, not a note in your calendar for three weeks' time.

• Suicidal thoughts, a plan, or an intention to act. Roughly half of people who die by suicide have seen a clinician in the preceding month, which means the appointment is not a protective barrier on its own. If you are thinking about ending your life, or if you have started giving possessions away, writing notes, or researching methods, that is a 999 or 988 call, not a message to your prescriber's admin inbox. In the US you can call or text 988; in the UK, Samaritans on 116 123.
• Self-harm urges that feel new or hard to resist. A person who has never cut, burned, or otherwise injured themselves and suddenly feels compelled to is describing something clinicians treat as an escalation, not a side effect to ride out. The same applies if an old pattern returns with more force than before.
• Severe agitation, akathisia, or an inability to sit still. Akathisia is an inner restlessness that people describe as crawling out of their skin, and it is a known precursor to impulsive self-harm in a small but real number of patients. It can appear within days of a dose increase, which is exactly what a prescriber might have done for presumed poop-out. If you cannot stay seated through a meal or an episode of television, say so the same day.
• Fever, tremor, sweating, confusion, or a racing heart together. That cluster is the classic picture of serotonin syndrome, and it becomes dangerous when it includes muscle rigidity, hyperthermia above 38.5 °C, or a heart rate over 120 bpm at rest. It is most likely after a dose increase, after adding a second serotonergic drug such as tramadol, triptans, or linezolid, or after combining an SSRI with an MAOI. Fluoxetine's long half-life of 4–6 days means it needs about five weeks to clear before an MAOI can be started safely; paroxetine, at roughly 21 hours, needs far less. Get medical help rather than waiting to see whether it settles.
• No food and no sleep for several days running. Going 72 hours or more without meaningful sleep, or losing the ability to eat without nausea or dread, is a medical problem in its own right. It dehydrates you, destabilises electrolytes, and makes every psychiatric symptom worse. Sleep deprivation alone can trigger mania in someone with a previously undiagnosed bipolar disorder, which is one reason a sudden surge of energy and reduced need for sleep should also prompt a call.
• A sudden switch from flat to unusually wired or grandiose. Feeling fantastic after months of numbness is not necessarily recovery. If you are sleeping four hours, spending money you do not have, or talking faster than people can follow, that is a red flag for a mixed or manic episode, and antidepressants can unmask bipolar disorder at exactly the 3–12 month mark.
• Chest pain, breathlessness, fainting, or a seizure. SSRIs and related drugs can prolong the QT interval on an ECG, particularly citalopram above 40 mg in adults over 65 or escitalopram above 20 mg. Fainting, palpitations with dizziness, or any first-ever seizure needs urgent assessment, not a wait-and-see.

The item people most often get wrong is agitation. A patient who calls their surgery reporting restlessness and insomnia four days after a dose bump is frequently told to persevere because SSRIs "take time to work." That advice is right for nausea and headache and wrong for akathisia, which tends to worsen rather than settle with continued dosing. If the sense of inner unrest is severe enough that you are pacing, unable to watch a film, or having thoughts of hurting yourself to make it stop, the correct move is to be seen today and say the word akathisia out loud.

The role of non-drug treatments

Medication is not the only lever, and for someone whose SSRI has stopped carrying the full load, it is often not the most powerful one. Cognitive behavioral therapy has the strongest relapse-prevention evidence of any non-drug option: a 2023 meta-analysis in Psychotherapy and Psychosomatics covering 12 trials and roughly 2,800 patients found that adding CBT to antidepressant treatment cut the risk of relapse by about 30% over 12 to 24 months compared with medication alone. The mechanism is unglamorous. CBT gives you a way to catch a low mood before it becomes a week of withdrawal and self-criticism, which is exactly the spiral that makes a partial drug response look like a full relapse.

Lifestyle factors matter more than most prescribers have time to say out loud. A 2023 BMJ meta-analysis of 218 randomised trials found that 150 minutes a week of moderate aerobic exercise — brisk walking counts — produced antidepressant effects comparable to first-line medication in mild-to-moderate depression, with the strongest signal at higher intensities. Sleep is the other half: fewer than six hours a night predicts poor SSRI response, and treating insomnia with CBT-I (not a sleeping tablet) improves daytime mood scores independently of the antidepressant. If you are sleeping four hours and calling your sertraline useless, fix the sleep first.

For severe or treatment-resistant cases, neuromodulation enters the picture. Transcranial magnetic stimulation (TMS) is FDA-cleared for major depression that has not responded to at least one antidepressant, and a typical course is 20 to 30 daily sessions over four to six weeks, with response rates around 50% and remission around 30% in registry data. Electroconvulsive therapy (ECT) remains the most effective single treatment for severe, psychotic, or life-threatening depression, with response rates of 70 to 90% in the acute phase — it is not a last resort for the hopeless, it is a first-line option for a specific clinical picture. Neither is a substitute for therapy or sleep, and neither is something you ask for on a bad Tuesday.

The honest trade-off: if your symptoms are mild and you have never had therapy, try CBT and sleep repair before adding a second drug. If your symptoms are moderate to severe and you have already done that work, the non-drug options are adjuncts, not replacements, and the conversation should be about TMS or a medication switch — not about white-knuckling it until spring. Bring this section to your next appointment as a list of questions, not a request.

Frequently Asked Questions

How long does antidepressant poop-out last?

It does not resolve on its own. Poop-out persists until a prescriber changes something about the regimen, whether that is dose, drug, or augmentation. Once a change is made, most patients notice meaningful improvement within 2 to 8 weeks, the same window used for treating a first episode.

Can you increase the dose to fix poop-out?

Sometimes, but the fix is often temporary. A dose bump can restore response for a few months before the same fading recurs, a pattern sometimes called tachyphylaxis, and side effects put a ceiling on how high a prescriber is willing to go. Sertraline above 200 mg daily, for example, is off the standard range.

What percentage of people experience antidepressant poop-out?

Published estimates run from roughly 9% to 33% of long-term users. The wide range reflects differences in how poop-out is defined, how long patients are followed, and whether the population is drawn from primary care or specialty mood clinics. A 2022 analysis in Psychotherapy and Psychosomatics put the figure near 20% for maintenance-phase relapse on continuing treatment.

Is poop-out the same as tolerance?

No. Tolerance means you need more of a drug to get the same effect, the classic pattern with opioids or benzodiazepines. Tachyphylaxis, the technical term for poop-out, means the drug stops working even when the dose stays constant. The distinction matters because it shapes whether a prescriber raises the dose or switches drug class.

Should I switch antidepressants if mine stops working?

Switching is one of the most common and best-supported moves, with roughly 50% to 60% of people responding to a second antidepressant after one fails. The STAR*D trial, published in 2006, found response rates fell with each successive switch, so the first change is often the most productive. Do it with a prescriber, not alone, because washout periods differ by drug.

Can popping out happen with all antidepressants?

Yes. Poop-out has been reported across SSRIs, SNRIs, and bupropion, and case reports exist for older classes such as tricyclics. Most formal research focuses on SSRIs because they dominate prescriptions, not because other classes are immune. Anyone on long-term maintenance therapy should treat fading response as a reason for a review, not a reason to stop abruptly.